Marimastat

Marimastat
	File:Marimastat.png
Systematic (IUPAC) name
	N-[2,2-dimethyl-1- (methylcarbamoyl)propyl]-2- [hydroxy-(hydroxycarbamoyl)methyl]- 4- methyl-pentanamide
Clinical data
Routes of; administration	oral
Identifiers
CAS Number	154039-60-8
ATC code	none
PubChem	CID 119031
DrugBank	APRD00559
Chemical data
Formula	C15H29N3O5
Molar mass	331.408 g/mol[[Script error: No such module "String".]]
(verify)

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Marimastat was a proposed antineoplastic drug developed by British Biotech. It acted as a broad-spectrum matrix metalloproteinase inhibitor.^[1]^[2]

Marimastat performed poorly in clinical trials,^[3] and development was terminated.^{[citation needed]}

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

This pharmacology-related article is a stub. You can help ssf by expanding it.

↑ "Marimastat". National Cancer Institute.
↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
↑ Sparano, JA (2004). "Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196". J Clin Oncol. 22 (23): 4683–90. PMID 15570070.